GEMINI - Cancer Genetic Testing in Ethnic Populations

Primary

• Prevalence of pathogenic germline mutations in enrolled patients within each cancer site

  Will identify the prevalence of pathogenic germline mutations in enrolled patients within each cancer site, age (\< 60 years old versus (vs.) \>= 60 years old), and stage (early vs. advanced) via descriptive statistics.

  Time frame: Study completion (2 years)

• Prevalence of positive pathogenic germline mutations

  Will determine whether the prevalence of positive pathogenic germline mutations differs between cancer sites, age of diagnosis, and stage of diagnosis using logistic regression analysis across all cancer site groups and pairwise post-hoc analyses using Tukey's correction for multiple comparisons across pairs of cancer sites and chi-square tests of differences between age and stage groups.

  Time frame: Study completion (2 years)

• Rate of mutation detection via genetic testing to clinical practice guidelines of traditional family history criteria

  Will compare the rate of mutation detection via genetic testing to clinical practice guidelines of traditional family history criteria within cancer site, age, and stage using logistic regression and pairwise post-hoc analyses as needed.

  Time frame: Study completion (2 years)

• Impact of germline genetic testing on both therapeutic management and targeted cancer prevention

  Will assess the impact of germline genetic testing on both therapeutic management and targeted cancer prevention in family members using logistic regression and pairwise post-hoc analyses as needed.

  Time frame: Study completion (2 years)